Currently, over 200 recombinant proteins have been approved by the FDA for treatment of a wide range of diseases. However, the clinical use of most protein drugs is limited by their toxicity, short half-life, and low solubility and bioavailability. In this regard, the development metabolizable agents of targeted delivery and prolongation of the life of therapeutic proteins is currently of relevance. Recently, plasma lipoproteins and their protein components, apolipoproteins, have been studied as a new nanoplatform for the transport of various therapeutic molecules. Apolipoprotein A-I (apoA-I) has a long half-life in the body, is not immunogenic and binds to receptors of many cell types. In our studies, genetically engineered constructs were created in which аpoA-I was fused with clinically used cytokines – granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-СSF) and interferon-α2b (IFN). Methylotrophic yeast Pichia pastoris X-33 was used for the production of chimeric cytokines. The study of the biological properties of cytokines that make up the chimeras showed that their activity remains comparable to the activity of their authentic forms. Furthermore, G-CSF-ApoA-I and GM-CSF-ApoA-I exhibited properties somewhat different from their authentic forms – the chimeras more efficiently increased the viability and decreased apoptosis of human bone marrow cells (BMCs). G-CSF-ApoA-I decreased the number of abnormally segmented neutrophils and, unlike G-CSF, increased the proliferation of monocytic BMCs. ApoA-I-fusion technology has been used to produce long-acting IFN. In experiments on mice, it was demonstrated that the half-life of chimeric IFN-ApoA-I was 1.8 times that of IFN.